China Overhauls ADR Reporting Regulations That Place Additional Responsibility On Drug Makers
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - China's State FDA released new guidelines for adverse drug reaction reporting May 24 that will dramatically increase the postmarket reporting responsibilities of manufacturers, distributors and hospitals
You may also be interested in...
Draft guidelines from SFDA would impact both foreign and domestic pharmaceutical manufacturers.